SUBSCRIBE
SUBSCRIBE
News   Policy

UCB Group to Launch Epilepsy Drug in Autumn

June 27, 2008 | 
1 min read

BRUSSELS, June 27 (Reuters) - Shares in UCB SA jumped on Friday as the Belgian pharmaceutical group said it aimed to launch its new epilepsy drug Vimpat in the autumn, after winning a green light from the European Medicines Agency.

Regulatory Europe
MORE ON THIS TOPIC
The EMA's former headquarters in London
Europe
Biogen, Eisai Continue Leqembi’s European Rally as CHMP Reaffirms Positive Opinion
March 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Editorial
Transparency Missing in Action at HHS Despite Leaders’ Calls for Clarity
February 28, 2025
 · 
4 min read
 · 
Heather McKenzie
Pictured: Regeneron logo on a light brown building
Lymphoma
Regeneron Narrows Approval Aspirations for Lymphoma Bispecific, Citing ‘Competitor Developments’
February 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: A syringe broken in half with long hallway in background/Nicole Bean for BioSpace
Vaccines
Meeting of FDA’s Vaccines Advisory Panel Canceled as Kennedy Settles Into HHS
February 27, 2025
 · 
2 min read
 · 
Tristan Manalac